Shandong Luye Pharma 5-HT2A receptor compound P25a

Shandong Luye Pharma 5-HT2A receptor compound P25a: sourced facts only. name: "The optimal compound P25a exhibited better 5-HT2A receptor inverse agonist activity and lower hERG inhibition than that of pimavanserin." [PMID:40784305]; target: "The optimal compound P25a exhibited better 5-HT2A receptor inverse agonist activity and lower hERG inhibition than that of pimavanserin." [PMID:40784305]; developer: "School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, China; State Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong Luye Pharmaceutical Co., Ltd., Yantai, Shandong, 264003, China." [PMID:40784305]; stage: "Compound P25a demonstrated higher functional activities in both DOI-induced head twitches model and MK801-induced hyperactivity model." [PMID:40784305]